Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × niraparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 25 Neoplasms 10 Breast Neoplasms 8 Fallopian Tube Neoplasms 6 Neoplasm Metastasis 4 Prostatic Neoplasms 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms, Castration-Resistant 2 Melanoma 2 Carcinoma, Ovarian Epithelial 2 Advanced Solid Tumor 2 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Tumor 1 Recurrence 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 HER2-negative Metastatic Breast Cancer 1 Glioblastoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 46 Cyclophosphamide 28 Lenalidomide 27 pomalidomide 24 Rituximab 23 venetoclax 22 fludarabine 21 Bortezomib 20 Paclitaxel 18 Gemcitabine 18 carfilzomib 16 Carboplatin 15 pembrolizumab 14 Cisplatin 14 daratumumab 13 Docetaxel 12 Calcium Dobesilate 12 Cytarabine 11 Azacitidine 11 obinutuzumab 10 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 ibrutinib 9 durvalumab 8 blinatumomab 8 Injections 8 Cetuximab 8 zanubrutinib 7 selinexor 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡